CS
CRNX icon

Candriam SCA’s Crinetics Pharmaceuticals CRNX Stock Holding History

Candriam SCA’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.2M Hold
830,961
– – 0.16% 140
2025
Q4 		$38.7M Buy
830,961
+85,867
+12% +$3.82M 0.19% 121
2025
Q3 		$31M Buy
745,094
+51,225
+7% +$1.64M 0.16% 130
2025
Q2 		$20M Buy
693,869
+204,958
+42% +$6.33M 0.12% 165
2025
Q1 		$16.4M Buy
+488,911
New +$18.3M 0.1% 181
2024
Q2 		– Sell
-88,005
Closed -$4.12M – 695
2024
Q1 		$4.12M Sell
88,005
-200,006
-69% -$7.83M 0.03% 375
2023
Q4 		$10.2M Buy
+288,011
New +$8.83M 0.07% 245

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return